Shareholders Approve Massive Dilution and Reverse Stock Split for Tevogen Bio
TVGN sits 26% above its 52-week low of $0.23 on light trading volume (0.2× avg).
Summary
Tevogen Bio Holdings Inc. shareholders approved a 100 million share increase to its equity incentive plan, representing nearly 50% potential dilution, and authorized a reverse stock split at a ratio between 1:25 and 1:85.
Key Events · Corporate Governance and Compliance · TVGN
-
Shareholders Approve 100 Million Share Incentive Plan Increase
Stockholders approved an amendment to the 2024 Omnibus Incentive Plan, increasing the shares available for issuance by 100,000,000. This represents potential dilution of approximately 49.6% of the 201,522,282 shares outstanding as of January 21, 2026.
-
Reverse Stock Split Authorized by Shareholders
Shareholders approved an amendment to the Certificate of Incorporation to effect a reverse stock split at a ratio between 1:25 and 1:85, at the Board's discretion. This action is typically taken to increase share price and meet listing requirements.
Analysis · TVGN · Life Sciences
Tevogen Bio Holdings Inc. shareholders have approved two highly significant proposals: a 100 million share increase to its equity incentive plan and the authorization for a reverse stock split. The incentive plan increase represents nearly 50% potential dilution of the company's currently outstanding shares, which is a substantial overhang for investors. The approval of a reverse stock split, with a ratio between 1:25 and 1:85, is typically a measure taken by companies trading at very low prices to boost their share price and meet exchange listing requirements. These actions, following previous proxy filings (PRE 14A on January 16, 2026, and DEF 14A on January 26, 2026) seeking these approvals, indicate the company is taking aggressive steps to manage its capital structure and address its low stock price. This also comes shortly after the Board announced its intention to evaluate a special cash dividend (January 30, 2026 8-K), which may have been aimed at garnering shareholder support for these dilutive measures.
At the time of this filing, TVGN was trading at $0.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $58.3M. The 52-week trading range was $0.23 to $1.51. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.